PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
Authors:
- 1 August 2019
- journal article
- editorial
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (8) , 1323-1326
Abstract
No abstract availableFunding Information
- University of Texas MD Anderson Cancer Center
This publication has 25 references indexed in Scilit:
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionClinical Cancer Research, 2017
- Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerOncotarget, 2017
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung CancerClinical Cancer Research, 2017
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast CancerJNCI: Journal of the National Cancer Institute, 2016
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibitionOncotarget, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 MutationJournal of Clinical Oncology, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014